Skip to content
ChickenStockChickenStock
Research019170
Shinpoong Pharmaceutical logo

Shinpoong Pharmaceutical (019170) stock

KOSPI · Pharmaceuticals

KRW 7,920-1.37%(-110)

As of the Nov 13 regular-session close (Korea)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-509.27x

Net loss — not comparable

P/B

1.49x

P/S

1.74x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 63.9 billion-KRW 8 billion-KRW 8 billion+9.0%
Q1 2026Consolidated · Filed May 15, 2026KRW 54.5 billion-KRW 400 millionKRW 400 million-1.6%
Q4 2025Consolidated · Filed Mar 20, 2026KRW 58 billionKRW 3.9 billionKRW 500 million—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 62.6 billionKRW 7.2 billionKRW 6.4 billion+12.2%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 58.6 billionKRW 4.9 billionKRW 2.8 billion+4.6%
Q1 2025Consolidated · Filed May 15, 2025KRW 55.4 billion-KRW 1.8 billion-KRW 1.3 billion+2.6%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 20, 2026KRW 234.7 billionKRW 14.3 billionKRW 8.4 billion—
FY2024Consolidated · Filed Aug 14, 2025KRW 221.1 billion-KRW 20.5 billion-KRW 15.4 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
10.06%
Of trading value on Nov 13, 2026
Short-sale value
KRW 160 million
Previous 20-day average 8.09%
Net short position
1,389,213 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
3,931,787 shares
As of Nov 13, 2026 · 7.50% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 202610.06%KRW 160 million
Nov 12, 202620.40%KRW 330 million
Nov 11, 202611.53%KRW 170 million
Nov 10, 20267.98%KRW 110 million
Nov 9, 20269.69%KRW 180 million
Nov 6, 20268.94%KRW 210 million
Nov 5, 202610.18%KRW 280 million
Nov 4, 202614.01%KRW 440 million
Nov 3, 20266.93%KRW 150 million
Nov 2, 20264.10%KRW 80 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Shinpoong Pharmaceutical (019170) stock information

KOSPI

Shinpoong Pharmaceutical (019170) is listed on KOSPI. Its market capitalization is about KRW 415.2 billion. On trailing-twelve-month earnings the P/E ratio is -509.27, and the P/B ratio is 1.49. Return on equity is -0.3%. These figures are computed in-house from official filings and are reference information only.

Shinpoong Pharmaceutical — frequently asked questions

What is the P/E ratio of Shinpoong Pharmaceutical (019170)?
On a trailing-twelve-month basis, 019170 trades at a P/E ratio of -509.27. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Shinpoong Pharmaceutical?
019170 has a market capitalization of about KRW 415.2 billion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.